• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

chart

By Nascent Biotech
 Posted June 14, 2022
 In
chart2022-06-142022-06-14http://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttp://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.png200px200px
0

Recent Posts
  • Letter to Shareholders from Sean Carrick
    Letter to Shareholders from Sean Carrick
  • Message From Senior Management
    Message From Senior Management
  • VIDEO: Nascent Biotech CEO Sean Carrick at the Emerging Grown Conference
    VIDEO: Nascent Biotech CEO Sean Carrick at the Emerging Grown Conference
  • Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
    Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.